RU2020109130A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020109130A3 RU2020109130A3 RU2020109130A RU2020109130A RU2020109130A3 RU 2020109130 A3 RU2020109130 A3 RU 2020109130A3 RU 2020109130 A RU2020109130 A RU 2020109130A RU 2020109130 A RU2020109130 A RU 2020109130A RU 2020109130 A3 RU2020109130 A3 RU 2020109130A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187684.0A EP3446704A1 (en) | 2017-08-24 | 2017-08-24 | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| EP17187684.0 | 2017-08-24 | ||
| PCT/EP2018/050273 WO2019037898A1 (en) | 2017-08-24 | 2018-01-05 | [6R] -MTHF - EFFECTIVE ALTERNATIVE TO FOLATE IN CHEMOTHERAPY BASED ON 5-FLUOROURACILE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020109130A3 true RU2020109130A3 (cg-RX-API-DMAC10.html) | 2021-09-24 |
| RU2020109130A RU2020109130A (ru) | 2021-09-24 |
| RU2763934C2 RU2763934C2 (ru) | 2022-01-11 |
Family
ID=59702573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020109130A RU2763934C2 (ru) | 2017-08-24 | 2018-01-05 | [6r]-mthf - эффективная фолатная альтернатива в химиотерапии на основе 5-фторурацила |
Country Status (19)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| US20240350495A1 (en) * | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of carcinoma |
| EP4450071A1 (en) | 2023-04-20 | 2024-10-23 | Isofol Medical AB | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer |
| US20240350467A1 (en) * | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer |
| EP4534088A1 (en) | 2023-10-04 | 2025-04-09 | Isofol Medical AB | Arfolitixorin for use in vitamin b6-enhanced, 5-fluorouracil-based chemotherapy of carcinomas |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376658A (en) | 1990-05-11 | 1994-12-27 | University Of Southern California | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CN1942189A (zh) * | 2004-04-02 | 2007-04-04 | 阿德文特克斯药物有限公司 | 5,10－亚甲基四氢叶酸在癌症治疗中的用途 |
| JP2007531728A (ja) * | 2004-04-02 | 2007-11-08 | アドベントルクス ファーマシューティカルズ， インコーポレイテッド | 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 |
| KR20070019725A (ko) | 2004-04-02 | 2007-02-15 | 어드벤트륵스 파마슈티칼스, 인크. | 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도 |
| WO2005117876A1 (en) | 2004-06-01 | 2005-12-15 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
| WO2007064968A2 (en) * | 2005-12-02 | 2007-06-07 | Adventrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate |
| CA2663599A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| WO2008109349A1 (en) | 2007-03-06 | 2008-09-12 | Adventrx Pharmaceuticals, Inc. | Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine |
| EP2173875B1 (en) | 2007-06-15 | 2017-08-30 | Cequent Pharmaceuticals, Inc. | Bacteria mediated gene silencing |
| RU2482496C2 (ru) | 2008-09-26 | 2013-05-20 | Эститю Де Кансероложи Де Л'Вест | Оптимизация индивидуальных доз 5-фторурацила при режиме folfox |
| CA2796205A1 (en) | 2010-04-15 | 2011-10-20 | Vegenics Pty Limited | Combination treatment with vegf-c antagonists |
| EP2617422A1 (en) | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
| EP2617421A1 (en) | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| RU2728571C2 (ru) | 2015-07-27 | 2020-07-30 | Инносимаб Пте Лтд | Лечение пациентов с диагнозом аденокарцинома протоков поджелудочной железы с использованием моноклональных антител к рецептору эпидермального фактора роста (egfr) |
| EP3446703A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| EP3305318A1 (en) | 2016-10-05 | 2018-04-11 | Isofol Medical AB | [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy |
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| WO2018150264A1 (en) | 2017-02-14 | 2018-08-23 | Isofol Medical Ab | METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION |
| US20230116137A1 (en) * | 2017-08-24 | 2023-04-13 | Isofol Medical Ab | Methods for treating colorectal and metastatic colorectal cancers |
| MX2020007009A (es) | 2018-01-05 | 2020-11-11 | Isofol Medical Ab | Metodos para tratar canceres colorrectales metastasicos y colorrectales. |
| CN113286589A (zh) | 2018-05-30 | 2021-08-20 | 大卫·马舒瓦尔 | 用于治疗癌症的方法和药物组合物 |
| WO2023046304A1 (en) | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
| WO2023046307A1 (en) | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
| WO2023046305A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer |
| US20230095428A1 (en) * | 2021-09-28 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
| US20230097085A1 (en) | 2021-09-28 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
| US20240350495A1 (en) | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of carcinoma |
| US20240350467A1 (en) | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer |
-
2017
- 2017-08-24 EP EP17187684.0A patent/EP3446704A1/en not_active Withdrawn
-
2018
- 2018-01-05 HU HUE18150455A patent/HUE057332T2/hu unknown
- 2018-01-05 PT PT181504556T patent/PT3446705T/pt unknown
- 2018-01-05 DK DK18150455.6T patent/DK3446705T3/da active
- 2018-01-05 MX MX2020002053A patent/MX2020002053A/es unknown
- 2018-01-05 CA CA3073555A patent/CA3073555C/en active Active
- 2018-01-05 AU AU2018320069A patent/AU2018320069B2/en active Active
- 2018-01-05 EP EP18150455.6A patent/EP3446705B1/en active Active
- 2018-01-05 RU RU2020109130A patent/RU2763934C2/ru active
- 2018-01-05 SG SG11202001372TA patent/SG11202001372TA/en unknown
- 2018-01-05 BR BR112020003585-8A patent/BR112020003585A2/pt not_active IP Right Cessation
- 2018-01-05 WO PCT/EP2018/050273 patent/WO2019037898A1/en not_active Ceased
- 2018-01-05 CN CN201880008885.6A patent/CN110290802A/zh active Pending
- 2018-01-05 PL PL18150455T patent/PL3446705T3/pl unknown
- 2018-01-05 JP JP2020510518A patent/JP7356411B2/ja active Active
- 2018-01-05 ES ES18150455T patent/ES2901621T3/es active Active
- 2018-01-05 IL IL272874A patent/IL272874B2/en unknown
- 2018-01-05 EP EP18700857.8A patent/EP3672623A1/en not_active Withdrawn
- 2018-01-09 SG SG10201800195XA patent/SG10201800195XA/en unknown
- 2018-01-09 US US15/865,870 patent/US11013744B2/en active Active
- 2018-01-09 KR KR1020180002962A patent/KR102216031B1/ko not_active Expired - Fee Related
- 2018-01-09 CA CA2991357A patent/CA2991357A1/en not_active Abandoned
- 2018-01-09 TW TW107100834A patent/TWI752147B/zh not_active IP Right Cessation
- 2018-02-08 JP JP2018021069A patent/JP2019038797A/ja active Pending
-
2021
- 2021-05-24 US US17/329,075 patent/US12527796B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122021000189A2 (cg-RX-API-DMAC10.html) | ||
| BR112019008823A2 (cg-RX-API-DMAC10.html) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020011860B1 (pt) | Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho | |
| BR112020006283B1 (pt) | Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR112020003314B1 (pt) | Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica | |
| BR112020003112B1 (pt) | Método de garantir a viabilidade de uma máquina para uma tarefa agendada | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112020001262B1 (pt) | Processo para preparar uma composição de entrega de fármaco | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR112019027876B1 (pt) | Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações | |
| BR112019026818B1 (pt) | Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador | |
| BR102018011961B1 (pt) | Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR102018003507B1 (pt) | Sistema de isolamento de tensão de tambor de guincho | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019017156B1 (pt) | Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador | |
| BR112019014017B1 (pt) | Dispositivo de medição da quantidade de oxigênio presente em um gás, e, módulo de separação de ar | |
| BR112020006250B1 (pt) | Primeira estação base e método de controle de estado em uma primeira estação base | |
| BR112020007888B1 (pt) | Terminal e método de radiocomunicação para um terminal | |
| BR112020004962B1 (pt) | Terminal que controla a recepção de um sinal de referência de um sistema sem fio com base em informações que permitem a multiplexação de frequências entre um sinal de dados e um sinal de referência |